Fujifilm plots $928M infusion at Danish biologics plant to double production capacity

Fujifilm made a massive investment in a former Biogen biologics facility in Denmark last year to help realize its global CDMO expansion plans. With that nearly $1 billion check behind it, Fujifilm is shelling out an almost equally gigantic infusion to double capacity at the Danish plant. Fujifilm will dole out a whopping $928 million at a former Biogen site in Denmark it acquired in August for $890 million, the Japanese drugmaker said Tuesday. The company's major capital outlay for its Fujifilm Diosynth Biotechnologies CDMO site will dramatically expand the facility's bulk drug manufacturing capacity, finish/fill capabilities and packaging output by fall 2023. Fujifilm's infusion into its Denmark site comes weeks after the Japanese drugmaker agreed to set aside manufacturing space at the site for the Bill Gates-funded COVID-19 Therapeutics Accelerator. In late April, Fujifilm agreed to dedicate room at the Hillerød, Denmark, facility and 'work with a selected pharmaceutical partner in supporting the swift manufacture and dedicated supply for patients with COVID-19 in lower-income countries,' the drugmaker said in a release.